Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML.

Trial Profile

Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Arsenic trioxide (Primary) ; Dasatinib; Imatinib; Nilotinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Dec 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top